Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey

Eur J Heart Fail. 2007 Dec;9(12):1205-11. doi: 10.1016/j.ejheart.2007.09.008.

Abstract

Background: Recent registries have shown that recommended drugs for the treatment of chronic heart failure (CHF) are under-prescribed in daily practice.

Aims: To determine prescription rates of CHF drugs, and to assess predictive factors for drug prescription using data from a large panel of French cardiologists.

Methods and results: We included 1919 outpatients, with NYHA class II-IV heart failure and a left ventricular ejection fraction <40%. The most frequently prescribed drugs were diuretics (83%), angiotensin converting enzyme inhibitors (ACE-I) (71%), beta-blockers (65%), spironolactone (35%) and angiotensin receptor blockers (ARB) (21%); 61% of patients received a combination of a beta-blocker and an ACE-I or ARB. Target doses were reached in 49% of the patients for ACE-I, but in only 18% for beta-blockers and in 9% for ARBs. Multivariate analyses showed that age >75 years was an independent factor associated with under-prescription of ACE-I-ARBs, beta-blockers or spironolactone. Renal failure was associated with a lower prescription of ACE-I-ARB and spironolactone, and asthma was a predictor of under-prescription of beta-blockers.

Conclusions: In this contemporary survey, prescription rates of CHF drugs were higher than previously reported. However, dosages were lower than those recommended in guidelines. Age remained an independent predictor of under-prescription of CHF drugs.

Publication types

  • Comparative Study

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aged
  • Aged, 80 and over
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Diuretics / therapeutic use
  • Drug Dosage Calculations
  • Drug Prescriptions / standards*
  • Drug Prescriptions / statistics & numerical data
  • Female
  • Follow-Up Studies
  • France
  • Guideline Adherence*
  • Heart Failure / drug therapy*
  • Humans
  • Male
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Practice Guidelines as Topic*
  • Prognosis
  • Registries*
  • Retrospective Studies
  • Risk Factors

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Diuretics
  • Mineralocorticoid Receptor Antagonists